Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib: the Phase Iii, Randomised Impress Study
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Since the systematic review was performed, nivolumab has emerged for patients with SCC in the second- and third-line settings who experience progression during or after platinum-based therapy.
“Since the systematic review was performed for this guideline, nivolumab has emerged for patients with SCC in the second- and third-line settings who experience progression during or after platinum-based therapy.100”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T. S. K., Petrella, F., Spaggiari, L., & Rosell, R. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.9 · Cited by 1,121 · see citing works
Self-citationMasters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850 · see citing works
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665 · see citing works
Self-citationRefining the treatment of NSCLC according to histological and molecular subtypes
Thomas, A., Liu, S. V., Subramaniam, D. S., & Giaccone, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.90 · Cited by 320 · see citing works
The Evolution of Therapies in Non-Small Cell Lung Cancer
Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 126 · see citing works
Hanna, N. H., Johnson, D. H., Temin, S., & Masters, G. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.026716 · Cited by 100 · see citing works
Reguart, N., & Remon, J. (2015) · Future Oncology · doi:10.2217/fon.15.15 · Cited by 91 · see citing works
Zhou, C., & Yao, L. D. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.002 · Cited by 87 · see citing works
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Hirsh, V. (2015) · BioDrugs · doi:10.1007/s40259-015-0130-9 · Cited by 68 · see citing works
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
Dhillon, S. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0358-9 · Cited by 68 · see citing works
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
Maione, P., Sacco, P. C., Sgambato, A., Casaluce, F., Rossi, A., & Gridelli, C. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015595048 · Cited by 58 · see citing works
“The first-generation ALK inhibitor crizotinib, in a phase III study named PROFILE 1014, was recently established as the standard of care for patients with previously untreated advanced ALK-positive nonsquamous NSCLC [Mok et al. 2014].”
BackgroundLo, P. C., Dahlberg, S. E., Nishino, M., Johnson, B. E., Sequist, L. V. D., Jackman, D. M., Janne, P. A., & Oxnard, G. R. (2015) · Cancer · doi:10.1002/cncr.29397 · Cited by 54 · see citing works
Tartarone, A., & Lerose, R. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815587820 · Cited by 53 · see citing works
“…patients with locally advanced or metastatic EGFR Mut+ NSCLC, prior progression disease (PD) on first line gefitinib and no previous chemotherapy were randomized to begin chemotherapy with cisplatin and pemetrexed or to continue gefitinib with the same chemotherapy [Mok et al. 2014] (Figure 1).”
MethodYoshimura, N., Kudoh, S., Mitsuoka, S., Yoshimoto, N., Oka, T., Nakai, T., Suzumura, T., Matusura, K., Tochino, Y., Asai, K., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.002 · Cited by 49 · see citing works
Márquez-Medina, D., & Popat, S. (2015) · Future Oncology · doi:10.2217/fon.15.183 · Cited by 40 · see citing works
Matikas, A., Mistriotis, D., Georgoulias, V., & Kotsakis, A. P. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.013 · Cited by 34 · see citing works
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Santarpía, M., Gil, N., & Rosell, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1055252 · Cited by 34 · see citing works
“resistance to gefitinib because of a lack of PFS improvement with addition of gefitinib, compared to placebo [106].”
BackgroundChung, C. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215577810 · Cited by 31 · see citing works
Oronsky, B. T., Ma, P., Reid, T. R., Cabrales, P., Lybeck, M., Oronsky, A. L., Oronsky, N. C., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.11.001 · Cited by 30 · see citing works
Advances in Molecular Biology of Lung Disease
Rooney, C., & Sethi, T. (2015) · CHEST Journal · doi:10.1378/chest.14-2663 · Cited by 28 · see citing works
Yang, J. C., Srimuninnimit, V., Ahn, M., Lin, C., Kim, S., Tsai, C., Mok, T. S. K., Orlando, M., Puri, T., Wang, X., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.008 · Cited by 26 · see citing works
Self-citationZhao, B., Zhang, W., Yu, D., Xu, J., & Wei, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.011 · Cited by 23 · see citing works
Emerging paradigms in targeted treatments for Asian patients with NSCLC
Ke, E., Zhou, Q. H., & Wu, Y.-L. L. C. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1040391 · Cited by 20 · see citing works
Self-citationEGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression
Assche, K. V., Ferdinande, L., Lievens, Y. N., Vandecasteele, K., & Surmont, V. F. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00350 · Cited by 19 · see citing works
“The IMPRESS trial, a randomized phase III trial evaluating the addition of gefitinib to cisplatin/pemetrexed as second-line treatment after gefitinib failure, showed no clinical benefit for the combination therapy in comparison with doublet chemotherapy alone (27).”
MethodManaging Acquired Resistance in EGFR-Mutated Non–Small Cell Lung Cancer
Forde, P. M., & Ettinger, D. S. (2021) · Default Digital Object Group · doi:10.1200/adn.21.200653 · Cited by 19 · see citing works
Auliac, J. B., Fournier, C., Audigier-Valette, C., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0387-4 · Cited by 18 · see citing works
“Preliminary results of the IMPRESS study suggest little impact of continued EGFR TKI therapy plus chemotherapy in this situation [26].”
Masuda, T., Imai, H., Kuwako, T., Miura, Y., Yoshino, R., Kaira, K., Shimizu, K., Sunaga, N., Tomizawa, Y., Ishihara, S., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1297-8 · Cited by 16 · see citing works
“However, this combination failed to prolong the PFS and had a deleterious effect on OS [35].”
BackgroundGenerations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
Castellanos, E. H., & Horn, L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0365-1 · Cited by 12 · see citing works
10-year long-term survival of a metastaticEGFR-mutated nonsmall cell lung cancer patient
Kempf, E., Planchard, D., Chevalier, T. L., & Soria, J. (2015) · European Respiratory Journal · doi:10.1183/09031936.00017315 · Cited by 12 · see citing works
Self-citationXiao, B., Yang, J., Dong, J.-X., Ji, Z.-S., Si, H., Wang, W., & Rong-qing, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.7.2915 · Cited by 12 · see citing works
“…to Assess the Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC at ESMO 2014 congress showed that continuation of gefitinib in addition to pemetrexed/cisplatin would be of no clinical benefit for patients with NSCLC after progression on first-line gefitinib (Mok et al., 2014).”
BackgroundSelf-citationZerillo, J. A., Stuver, S. O., Fraile, B., Dodek, A., & Jacobson, J. O. (2015) · Journal of Oncology Practice · doi:10.1200/jop.2015.003921 · Cited by 9 · see citing works
AZD9291 in epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Stinchcombe, T. E. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.07.19 · Cited by 9 · see citing works
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer
Zimmermann, S., & Peters, S. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9560-6 · Cited by 8 · see citing works
Aggarwal, S., Patil, S., & Rohtagi, N. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_510_17 · Cited by 8 · see citing works
Shukuya, T., Ko, R., Mori, K. P., Kato, M., Yagishita, S., Kanemaru, R., Honma, Y., Shibayama, R., Koyama, R., Shimada, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2843-3 · Cited by 7 · see citing works
“IMPRESS trial (a study of IRESSA treatment beyond progression in addition to chemotherapy versus chemotherapy alone) showed no benefit in continuing gefitinib treatment combined with cisplatin plus pemetrexed compared with cisplatin plus pemetrexed alone after NSCLC patients harboring the EGFR mutation acquired resist…”
Melosky, B. L., Popat, S., & Gandara, D. R. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.019 · Cited by 8 · see citing works
(2015) · Journal of Pharmacovigilance · doi:10.4172/2329-6887.1000155 · Cited by 4 · see citing works
“The standard treatment at progression remains platinum-based chemotherapy [31].”
BackgroundQiao, X., Zhang, Y., Wang, J., Nong, J., Li, X., Yang, X., Lv, J., Zhang, H., Qin, N., Zhang, Q., et al. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12236 · Cited by 3 · see citing works
Self-citationBrosseau, S., Viala, M., Varga, A., Planchard, D., Besse, B., & Soria, J. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.05.001 · Cited by 4 · see citing works
Self-citationActualités 2014 : le point de vue du comité de rédaction du Bulletin du Cancer
Massard, C., Bay, J., André, T., et al. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2014.11.002 · Cited by 1 · see citing works
“comparant l'afatinib à une chimiothérapie à base de platine (LUX-Lung 6 et LUX-Lung 3) a montré pour la première fois qu'un TKI-EGFR allongeait la survie globale par rapport à la chimiothérapie dans cette indication (27,3 mois versus 24,3 mois ; p = 0,037) [67].”
BackgroundLiu, S. M., & Wu, Y.-L. L. C. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.5 · Cited by 1 · see citing works
Self-citationKrawczyk, P. A., Powrózek, T., Nicoś, M., et al. (2015) · Współczesna Onkologia · doi:10.5114/wo.2015.52660 · Cited by 1 · see citing works
Europäischer Krebskongress – ESMO 2014
Junker, A. (2015) · Der Onkologe · doi:10.1007/s00761-014-2865-1
Overcoming EGFR-TKI Resistance
Cappuzzo, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-20741-4_4
Cancers bronchiques non à petites cellules mutés ou réarrangés : de la premiere á la énième ligne
Raimbourg, J., & Douillard, J. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30032-5
Achievements in targeted therapies
Bironzo, P., Mele, T., & Novello, S. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10010714
Paolo, B., Teresa, M., & Silvia, N. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.erm6815
- Authors
- Mok, T. S. K., Wu, Y., Nakagawa, K., Kim, S., Yang, J., Ahn, M., Wang, J., Yang, J. C., Lu, Y., Atagi, S., Ponce, S., Shi, X., Webster, A., Jiang, H., & Soria, J.-C.
- Affiliations
- Chinese University of Hong Kong (HK)
- Guangdong General Hospital (CN)
- Kindai University (JP)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Peking University (CN)
- West China Hospital of Sichuan University (CN)
- Kinki Central Hospital (JP)
- Sichuan University (CN)
- Sungkyunkwan University (KR)
- AstraZeneca (United Kingdom) (GB)
- Guangdong Academy of Medical Sciences (CN)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 25
- Pages
- v1
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2269456081
- Cited by
- 46
- References
- 0
- Citations by year
- 2018: 1 · 2017: 4 · 2016: 1 · 2015: 39 · 2014: 1
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- gefitinib, EGFR-mutant non-small cell lung cancer, cisplatin/pemetrexed, second-line chemotherapy, progression-free survival, overall survival, gastrointestinal toxicity, interstitial lung disease, safety and tolerability, locally advanced or metastatic NSCLC
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
